Nektar Therapeutics (NKTR) Gross Margin (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly Gross Margin came in at 29.09% in Q1 2026, up 9410.0% year-on-year from 0.31% in Q1 2025, and down 70.91% quarter-over-quarter from 100.0% in Q4 2025.
Nektar Therapeutics (NKTR) Gross Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Gross Margin history runs 17 years deep, the most recent figure standing at 29.09% for Q1 2026.
- On a quarterly basis, Gross Margin rose 9410.0% year-over-year to 29.09% in Q1 2026; TTM through Mar 2026 was 67.65%, a 3508.0% increase from a year earlier, with the FY2025 full-year figure at 100.0%, up 4272.0% from the prior year.
- Gross Margin slipped to 29.09% in Q1 2026 per NKTR's latest filing, from 100.0% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q2 2025 and bottomed at 65.01% in Q1 2025.
- The 5-year median for Gross Margin is 55.78% (2023), against an average of 53.43%.
- Across the five-year window, Gross Margin slumped 11323 bps in 2025 and surged 9410 bps in 2026, its largest moves.
- Year by year, Gross Margin stood at 71.7% in 2022, then fell by 22 bps to 55.78% in 2023, then sank by 40 bps to 33.72% in 2024, then soared by 197 bps to 100.0% in 2025, then sank by 71 bps to 29.09% in 2026.
- Per Business Quant, the three latest NKTR Gross Margin figures stand at 29.09% (Q1 2026), 100.0% (Q4 2025), and 12.66% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | 29.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.09% |
| Dec 31, 2025 | 100.00% |
| Sep 30, 2025 | 12.66% |
| Jun 30, 2025 | 100.00% |
| Mar 31, 2025 | -65.01% |
| Dec 31, 2024 | 33.72% |
| Sep 30, 2024 | 54.35% |
| Jun 30, 2024 | 52.22% |
| Mar 31, 2024 | 48.22% |
| Dec 31, 2023 | 55.78% |
| Sep 30, 2023 | 48.51% |
| Jun 30, 2023 | 65.88% |
| Mar 31, 2023 | 67.31% |
| Dec 31, 2022 | 71.70% |
| Sep 30, 2022 | 78.95% |
| Jun 30, 2022 | 76.30% |
| Mar 31, 2022 | 78.59% |
| Dec 31, 2021 | 75.36% |
| Sep 30, 2021 | 78.69% |
| Jun 30, 2021 | 72.94% |